A Phase 2 interventional study of Seasonal Influenza Vaccine in Seasonal Influenza, sponsored by Novartis Vaccines. Completed at 6 sites in Italy. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-28.
Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 101 studies in Influenza, Human by Novartis — none open to participants now, none under way, none of them phase 3. Influenza, Human · Novartis.
Among the 101 studies in Influenza, Human by Novartis, this one is the 85th largest by enrollment of the 97 interventional ones that give a count, is one of 5 that started in 2011, is one of 42 in phase 2, and was the 76th registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →None of the 101 studies in Influenza, Human by Novartis is open now. The open studies under Influenza, Human, anywhere →
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
101 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 48 · Phase 3 45 · Phase 4 5
First in 2004; this study’s year is marked. 5 started in 2011.
This study's enrollment of 63 is below the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 270 across the 97 interventional studies, 4,279 across the 4 observational. Of the 100 that completed or were terminated, 48 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Vaccines, one of the names counted as Novartis. Under that name alone:
Novartis Vaccines is the lead sponsor of 165 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 101 studies in Influenza, Human by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and immunogenicity of a sub-unit, adjuvanted Influenza Vaccine Administered to Elderly Subjects.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
Biological: Seasonal Influenza Vaccine
This phase II is performed as a multicenter study in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
Percentage of Participants Who Achieved Seroconversion or Significant Increase in Single Radial Hemolysis (SRH) Area Against Each of Three Vaccine Strains After One Vaccination of FLUAD
Immunogenicity was measured as the percentage of participants who achieved seroconversion or significant increase in single radial hemolysis (SRH) area, against each of the three vaccine strains, three weeks after vaccination (day 22), evaluated using SRH assay. Seroconversion: proportion of participants with negative pre-vaccination serum and a post-vaccination serum area ≥ 25 mm2. Significant increase: proportion of participants with at least a 50% increase in area from positive pre-vaccination serum. Seroconversion or significant increase: proportion of participants with either seroconversion or significant increase. The European (Committee for Medicinal Products for Human Use \[CHMP\]) criterion is met, if percentage of participants achieving seroconversion or significant increase in SRH area is 30% (≥65 years).
Time frame: day 22
Geometric Mean Ratio of Participants Against Each of the Three Vaccine Strains After One Vaccination of FLUAD
Geometric mean ratio (GMR) of participants was calculated as the ratio of post-vaccination to pre-vaccination SRH geometric mean areas (GMAs), directed against each of the three vaccine strains, three weeks after FLUAD vaccination (day 22). The CHMP criterion was met if the geometric mean increase (GMR, day 22/day 1) in SRH antibody area is \>2.0 (≥65 years).
Time frame: day 22
Percentage of Participants Who Achieved SRH Area ≥25mm2 Against Each of the Three Vaccine Strains After One Vaccination of FLUAD
Immunogenicity was measured as the percentage of participants achieving SRH area ≥25 mm2 against each of the three vaccine strains at baseline (day 1) and three weeks after FLUAD vaccination (day 22). This criterion is met according to CHMP guideline if percentage of participants achieving SRH area ≥25 mm2 is 60% (≥65 years).
Time frame: day 22
Number of Participants Who Reported Solicited Local and Systemic Reactions
Safety was assessed for participants who reported solicited local and systemic reactions from day 1 up to and including day 4 after the FLUAD vaccination.
Time frame: 1 to 4 days post-vaccination
Overall, 63 participants were ≥65 years of age were enrolled at 4 sites in Italy.
| Milestone | FLUAD |
|---|---|
| Started | 63 |
| Completed | 62 |
| Not completed | 1 |
| Withdrew: Premature withdrawal | 1 |
Immunogenicity was measured as the percentage of participants who achieved seroconversion or significant increase in single radial hemolysis (SRH) area, against each of the three vaccine strains, three weeks after vaccination (day 22), evaluated using SRH assay. Seroconversion: proportion of participants with negative pre-vaccination serum and a post-vaccination serum area ≥ 25 mm2. Significant increase: proportion of participants with at least a 50% increase in area from positive pre-vaccination serum. Seroconversion or significant increase: proportion of participants with either seroconversion or significant increase. The European (Committee for Medicinal Products for Human Use \[CHMP\]) criterion is met, if percentage of participants achieving seroconversion or significant increase in SRH area is 30% (≥65 years).
| Percentage of participants | FLUAD |
|---|---|
| A/H1N1 (N= 62) | 69 (56 to 80) |
| A/H3N2 (N= 62) | 50 (37 to 63) |
| B (N= 62) | 26 (16 to 38) |
Safety was assessed for participants who reported solicited local and systemic reactions from day 1 up to and including day 4 after the FLUAD vaccination.
| Number of participants | FLUAD |
|---|---|
| Injection site ecchymosis (N= 62) | 3 |
| Injection site erythema (N= 62) | 7 |
| Injection site induration (N= 62) | 4 |
| Injection site swelling (N= 62) | 7 |
| Injection site pain (N= 62) | 21 |
| Chills Shivering (N= 62) | 4 |
| Malaise (N= 62) | 3 |
| Myalgia (N= 62) | 6 |
| Arthralgia (N= 62) | 4 |
| Headache (N= 62) | 4 |
| Sweating (N= 62) | 1 |
| Fatigue (N= 62) | 2 |
| Fever (≥38°C) (N= 61) | 0 |
Geometric mean ratio (GMR) of participants was calculated as the ratio of post-vaccination to pre-vaccination SRH geometric mean areas (GMAs), directed against each of the three vaccine strains, three weeks after FLUAD vaccination (day 22). The CHMP criterion was met if the geometric mean increase (GMR, day 22/day 1) in SRH antibody area is \>2.0 (≥65 years).
| Ratio | FLUAD |
|---|---|
| A/H1N1 (N= 62) | 2.54 (2.1 to 3.07) |
| A/H3N2 (N= 62) | 1.9 (1.63 to 2.2) |
| B (N= 62) | 1.36 (1.21 to 1.53) |
Immunogenicity was measured as the percentage of participants achieving SRH area ≥25 mm2 against each of the three vaccine strains at baseline (day 1) and three weeks after FLUAD vaccination (day 22). This criterion is met according to CHMP guideline if percentage of participants achieving SRH area ≥25 mm2 is 60% (≥65 years).
| Percentage of participants | FLUAD |
|---|---|
| A/H1N1 (N= 62) | 89 (78 to 95) |
| A/H3N2 (N= 62) | 69 (56 to 80) |
| B (N= 62) | 94 (84 to 98) |
Collected over From Day 1 through Day 22.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FLUAD | — | 0/63 (0%) | 6/63 (9.5%) |
| Event | FLUAD |
|---|---|
| Injection site erythemaGeneral disorders | 3/63 |
| Injection site haemorrhageGeneral disorders | 2/63 |
| Injection site indurationGeneral disorders | 2/63 |
| Injection site painGeneral disorders | 2/63 |
| Injection site swellingGeneral disorders | 2/63 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/63 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/63 |
| MastoiditisInfections and infestations | 1/63 |
Baseline analysis population was defined as all participants who were enrolled into the study.
| Age, Continuous(Years) | FLUAD |
|---|---|
| Mean | 73.2 ± 5.2 |
| Sex: Female, Male(Participants) | FLUAD |
|---|---|
| Female | 31 |
| Male | 32 |
The record gives a start of May 2011, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 4 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.